Table 2. The association between CXCR3 expression and clinicopathological factors in gastric cancer.
| Factor | Number of studies | Number of patients | Pooled OR (95% CI) |
P value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I2 (%) | P value | Model | |||||
| Age (old vs. young) | 5 | 716 | 0.67 (0.49–0.91) | 0.011 | 0.0 | 0.983 | Fixed |
| Gender (male vs. female) | 5 | 716 | 0.90 (0.63–1.27) | 0.541 | 0.0 | 0.418 | Fixed |
| Tumor size (≥5 vs. <5 cm) | 3 | 428 | 0.69 (0.45–1.04) | 0.077 | 0.0 | 0.997 | Fixed |
| Tumor grade (PD vs. WD MD) | 3 | 428 | 0.46 (0.29–0.73) | 0.001 | 0.0 | 0.599 | Fixed |
| Lauren classification (diffuse vs. intestinal) | 4 | 613 | 0.98 (0.71–1.36) | 0.914 | 0.0 | 0.949 | Fixed |
| Tumor stage (III IV vs. I II) | 5 | 716 | 0.57 (0.19–1.71) | 0.315 | 88.7 | <0.001 | Random |
| Lymph node metastasis (present vs. absent) | 3 | 517 | 0.47 (0.31–0.71) | <0.001 | 0.0 | 0.427 | Fixed |
| TNM stage (high vs. low) | 4 | 613 | 0.51 (0.35–0.74) | <0.001 | 0.0 | 0.826 | Fixed |
CI, confidence interval; CXCR3, CXC chemokine receptor 3; MD, moderately-differentiated; OR, odds ratio; PD, poorly-differentiated; TNM, tumor-node-metastasis; WD, well-differentiated.